Expressão protéica de VEGF, TGF-β1 e BMPR1B em tumores mamários de cadelas e sua importância no prognóstico
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório do Centro Universitário Braz Cubas |
Texto Completo: | https://repositorio.cruzeirodosul.edu.br/handle/123456789/2567 |
Resumo: | In Brazil, mammary tumors is the most common tumor in dogs. Surgery is the treatment of choice for most cases. Histopathologic evaluation and interpretation are extremely necessary to obtain a prognosis and help the clinician decide on whether or not adjuvant treatments as well as monitor this patient. In human breast tumors evaluation by immunohistochemical markers in order to obtain more prognostic information and help to decide on specific therapies for certain types of tumors it is fundamental and critical. In veterinary medicine, little is known about markers and prognostic factors in canine mammary tumors. The Vascular Endothelial Growth factor (VEGF) is the most prevalent and most powerful factor in the process of angiogenesis, stimulating endothelial cells growth and the survivability of vessels. The Transforming Growth Factor - β (TGF-β) is well known to contribute in the control of proliferation; cell differentiation, especially as antiproliferative factor in normal epithelial cells and in the early stages of oncogenesis but can also act as promoter of tumor progression and tumor angiogenesis. The Bone Morphogenetic Protein Receptor Type 1B (BMPR1B) is also part of the great family of TGF-β and is involved in promoting and inhibiting the development of cancer. In this study these markers were used with the aim to relate mammary benign tumors, malignant mammary tumors with low / intermediate grade and high-grade lesions with quantification of immunohistochemical expression of VEGF, TGF-β1 and BMPR1B with the data obtained for each individual patient for survival time and metastasis. These neoplasms were separated into three distinct groups: Group 1 - Simple adenoma (SA), Group 2 - Simple Adenocarcinoma (SA) and lowintermediate grade (I, II,) and Group 3 – Simple Adenocarcinoma grade III or undifferentiated with skin invasion and metastasis with a clinical diagnosis of inflammatory carcinoma. The results showed that for VEGF there was no correlation between the expression in all three groups, BMPR1B was one of the markers that was obtained higher scores negative of its expression in samples of group 1, 2 and 3. The TGF-β1 in the statistical analyzes showed correlation with the degree of malignancy between group 1 and group 3 (p = 0.038). None of the three markers was associated with survival time and recurrence of tumors, at KaplanMeier construction curve method and the log rank test. The data from our study suggest that among the evaluation of the markers VEGF, TGF-β1 and BMPR1B their expression in mammary canine tumor samples by immunohistochemistry examination, the TGF-β1 was the only one that can serve as a parameter of malignancy. |
id |
CUB_756c3d76d5f9dd79ad8d4aa9a964c60f |
---|---|
oai_identifier_str |
oai:repositorio.cruzeirodosul.edu.br:123456789/2567 |
network_acronym_str |
CUB |
network_name_str |
Repositório do Centro Universitário Braz Cubas |
repository_id_str |
|
spelling |
Expressão protéica de VEGF, TGF-β1 e BMPR1B em tumores mamários de cadelas e sua importância no prognósticoNeoplasia mamáriaCãesImunoistoquímicaMetástaseSobrevidaCNPQ::CIENCIAS BIOLOGICAS::BIOLOGIA GERALIn Brazil, mammary tumors is the most common tumor in dogs. Surgery is the treatment of choice for most cases. Histopathologic evaluation and interpretation are extremely necessary to obtain a prognosis and help the clinician decide on whether or not adjuvant treatments as well as monitor this patient. In human breast tumors evaluation by immunohistochemical markers in order to obtain more prognostic information and help to decide on specific therapies for certain types of tumors it is fundamental and critical. In veterinary medicine, little is known about markers and prognostic factors in canine mammary tumors. The Vascular Endothelial Growth factor (VEGF) is the most prevalent and most powerful factor in the process of angiogenesis, stimulating endothelial cells growth and the survivability of vessels. The Transforming Growth Factor - β (TGF-β) is well known to contribute in the control of proliferation; cell differentiation, especially as antiproliferative factor in normal epithelial cells and in the early stages of oncogenesis but can also act as promoter of tumor progression and tumor angiogenesis. The Bone Morphogenetic Protein Receptor Type 1B (BMPR1B) is also part of the great family of TGF-β and is involved in promoting and inhibiting the development of cancer. In this study these markers were used with the aim to relate mammary benign tumors, malignant mammary tumors with low / intermediate grade and high-grade lesions with quantification of immunohistochemical expression of VEGF, TGF-β1 and BMPR1B with the data obtained for each individual patient for survival time and metastasis. These neoplasms were separated into three distinct groups: Group 1 - Simple adenoma (SA), Group 2 - Simple Adenocarcinoma (SA) and lowintermediate grade (I, II,) and Group 3 – Simple Adenocarcinoma grade III or undifferentiated with skin invasion and metastasis with a clinical diagnosis of inflammatory carcinoma. The results showed that for VEGF there was no correlation between the expression in all three groups, BMPR1B was one of the markers that was obtained higher scores negative of its expression in samples of group 1, 2 and 3. The TGF-β1 in the statistical analyzes showed correlation with the degree of malignancy between group 1 and group 3 (p = 0.038). None of the three markers was associated with survival time and recurrence of tumors, at KaplanMeier construction curve method and the log rank test. The data from our study suggest that among the evaluation of the markers VEGF, TGF-β1 and BMPR1B their expression in mammary canine tumor samples by immunohistochemistry examination, the TGF-β1 was the only one that can serve as a parameter of malignancy.No Brasil o tumor de mama é o tumor mais frequente em cadelas. A cirurgia é o tratamento inicial de eleição para a grande maioria dos casos. A avaliação histopatológica e sua interpretação são extremamente necessárias para se obter um prognóstico e ajudar o clínico a decidir ou não sobre tratamentos adjuvantes bem como de como acompanhar este paciente. Em tumores de mama em seres humanos é de extrema e fundamental importância a avaliação imunoistoquímica através de marcadores para obte-se mais informações prognósticas e ajudar a decidir por terapias específicas para certos tipos de tumores. Dentro da medicina veterinária pouco se sabe sobre marcadores e fatores prognósticos em tumores de mama. O Fator de Crescimento do Endotélio Vascular (VEGF) é o fator mais predominante e mais potente no processo da angiogênese, estimulando o crescimento de células endoteliais e a sobrevivência dos vasos. O Fator de Crescimento Transformante – β (TGF-β) é mais conhecido por contribuir no controle, proliferação, diferenciação celular, principalmente como fator anti-proliferativo em células epiteliais normais e em estágios iniciais da oncogênese, porém também possui efeitos de promoção e de angiogênese tumoral. O Receptor da Proteína Óssea Morfogenética tipo 1B (BMPR1B) também faz parte da grande família dos TGF-β e está envolvido na promoção e na inibição do desenvolvimento do câncer. No presente trabalho estes marcadores foram utilizados com o objetivo de relacionar lesões neoplásicas mamárias benignas, malignas de baixo/intermediário grau e em lesões de alto grau com a quantificação da expressão imunoistoquímica de VEGF, TGF-β1 e BMPR1B aos dados de sobrevida e metástase de cada um dos pacientes. Separou-se estas neoplasias em três distintos grupos; Grupo 1 - Adenoma Simples (AS), Grupo 2- Adenocarcinoma Simples (AC) de baixa e intermediária graduação (I e II) e o Grupo 3- Adenocarcinoma Simples grau III ou indiferenciados com invasão cutâneo e metástase, com diagnóstico clínico de carcinoma inflamatório. Os resultados obtidos demonstram que para o VEGF não houve nenhuma correlação, sendo expresso de uma maneira ampla nos três grupos, a BMPR1B foi um dos marcadores que se obteve maior escore de negatividade em sua expressão tanto em amostras do grupo 1, 2 e 3. O TGF-β1 apresentou nas análises estatísticas correlação com o grau de malignidade entre o grupo 1 e o grupo 3 (p=0,038). Nenhum dos três marcadores apresentou associação com o tempo de sobrevida e recorrência dos tumores, pela análise da construção da curva de Kaplan-Meier e teste de log rank. Os dados obtidos em nosso estudo sugerem que entre as avaliações dos marcadores VEGF, TGF-β1 e BMPR1B avaliando-se suas expressões nas amostras de tumores de mamas por exame de imunoistoquímica o TGF-β1 foi o único que pode servir de parâmetro de malignidade entre os tumores de mamas em cadelas.Universidade PositivoBrasilPós-GraduaçãoPrograma de Pós-Graduação em Biotecnologia IndustrialUPCosta-Casagrande, Thaís Andradehttp://lattes.cnpq.br/0664201574685996Silva, Robson Fernando de Pasquale e2021-08-16T17:45:15Z20132021-08-16T17:45:15Z2013info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttps://repositorio.cruzeirodosul.edu.br/handle/123456789/2567porinfo:eu-repo/semantics/openAccessreponame:Repositório do Centro Universitário Braz Cubasinstname:Centro Universitário Braz Cubas (CUB)instacron:CUB2021-08-19T15:59:20Zoai:repositorio.cruzeirodosul.edu.br:123456789/2567Repositório InstitucionalPUBhttps://repositorio.brazcubas.edu.br/oai/requestbibli@brazcubas.edu.bropendoar:2021-08-19T15:59:20Repositório do Centro Universitário Braz Cubas - Centro Universitário Braz Cubas (CUB)false |
dc.title.none.fl_str_mv |
Expressão protéica de VEGF, TGF-β1 e BMPR1B em tumores mamários de cadelas e sua importância no prognóstico |
title |
Expressão protéica de VEGF, TGF-β1 e BMPR1B em tumores mamários de cadelas e sua importância no prognóstico |
spellingShingle |
Expressão protéica de VEGF, TGF-β1 e BMPR1B em tumores mamários de cadelas e sua importância no prognóstico Silva, Robson Fernando de Pasquale e Neoplasia mamária Cães Imunoistoquímica Metástase Sobrevida CNPQ::CIENCIAS BIOLOGICAS::BIOLOGIA GERAL |
title_short |
Expressão protéica de VEGF, TGF-β1 e BMPR1B em tumores mamários de cadelas e sua importância no prognóstico |
title_full |
Expressão protéica de VEGF, TGF-β1 e BMPR1B em tumores mamários de cadelas e sua importância no prognóstico |
title_fullStr |
Expressão protéica de VEGF, TGF-β1 e BMPR1B em tumores mamários de cadelas e sua importância no prognóstico |
title_full_unstemmed |
Expressão protéica de VEGF, TGF-β1 e BMPR1B em tumores mamários de cadelas e sua importância no prognóstico |
title_sort |
Expressão protéica de VEGF, TGF-β1 e BMPR1B em tumores mamários de cadelas e sua importância no prognóstico |
author |
Silva, Robson Fernando de Pasquale e |
author_facet |
Silva, Robson Fernando de Pasquale e |
author_role |
author |
dc.contributor.none.fl_str_mv |
Costa-Casagrande, Thaís Andrade http://lattes.cnpq.br/0664201574685996 |
dc.contributor.author.fl_str_mv |
Silva, Robson Fernando de Pasquale e |
dc.subject.por.fl_str_mv |
Neoplasia mamária Cães Imunoistoquímica Metástase Sobrevida CNPQ::CIENCIAS BIOLOGICAS::BIOLOGIA GERAL |
topic |
Neoplasia mamária Cães Imunoistoquímica Metástase Sobrevida CNPQ::CIENCIAS BIOLOGICAS::BIOLOGIA GERAL |
description |
In Brazil, mammary tumors is the most common tumor in dogs. Surgery is the treatment of choice for most cases. Histopathologic evaluation and interpretation are extremely necessary to obtain a prognosis and help the clinician decide on whether or not adjuvant treatments as well as monitor this patient. In human breast tumors evaluation by immunohistochemical markers in order to obtain more prognostic information and help to decide on specific therapies for certain types of tumors it is fundamental and critical. In veterinary medicine, little is known about markers and prognostic factors in canine mammary tumors. The Vascular Endothelial Growth factor (VEGF) is the most prevalent and most powerful factor in the process of angiogenesis, stimulating endothelial cells growth and the survivability of vessels. The Transforming Growth Factor - β (TGF-β) is well known to contribute in the control of proliferation; cell differentiation, especially as antiproliferative factor in normal epithelial cells and in the early stages of oncogenesis but can also act as promoter of tumor progression and tumor angiogenesis. The Bone Morphogenetic Protein Receptor Type 1B (BMPR1B) is also part of the great family of TGF-β and is involved in promoting and inhibiting the development of cancer. In this study these markers were used with the aim to relate mammary benign tumors, malignant mammary tumors with low / intermediate grade and high-grade lesions with quantification of immunohistochemical expression of VEGF, TGF-β1 and BMPR1B with the data obtained for each individual patient for survival time and metastasis. These neoplasms were separated into three distinct groups: Group 1 - Simple adenoma (SA), Group 2 - Simple Adenocarcinoma (SA) and lowintermediate grade (I, II,) and Group 3 – Simple Adenocarcinoma grade III or undifferentiated with skin invasion and metastasis with a clinical diagnosis of inflammatory carcinoma. The results showed that for VEGF there was no correlation between the expression in all three groups, BMPR1B was one of the markers that was obtained higher scores negative of its expression in samples of group 1, 2 and 3. The TGF-β1 in the statistical analyzes showed correlation with the degree of malignancy between group 1 and group 3 (p = 0.038). None of the three markers was associated with survival time and recurrence of tumors, at KaplanMeier construction curve method and the log rank test. The data from our study suggest that among the evaluation of the markers VEGF, TGF-β1 and BMPR1B their expression in mammary canine tumor samples by immunohistochemistry examination, the TGF-β1 was the only one that can serve as a parameter of malignancy. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013 2013 2021-08-16T17:45:15Z 2021-08-16T17:45:15Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://repositorio.cruzeirodosul.edu.br/handle/123456789/2567 |
url |
https://repositorio.cruzeirodosul.edu.br/handle/123456789/2567 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Positivo Brasil Pós-Graduação Programa de Pós-Graduação em Biotecnologia Industrial UP |
publisher.none.fl_str_mv |
Universidade Positivo Brasil Pós-Graduação Programa de Pós-Graduação em Biotecnologia Industrial UP |
dc.source.none.fl_str_mv |
reponame:Repositório do Centro Universitário Braz Cubas instname:Centro Universitário Braz Cubas (CUB) instacron:CUB |
instname_str |
Centro Universitário Braz Cubas (CUB) |
instacron_str |
CUB |
institution |
CUB |
reponame_str |
Repositório do Centro Universitário Braz Cubas |
collection |
Repositório do Centro Universitário Braz Cubas |
repository.name.fl_str_mv |
Repositório do Centro Universitário Braz Cubas - Centro Universitário Braz Cubas (CUB) |
repository.mail.fl_str_mv |
bibli@brazcubas.edu.br |
_version_ |
1798311360518422528 |